智通财经APP获悉，由于重磅抗癌药物热销，英国制药巨头阿斯利康(AZN.US)第二季度盈利超预期，当下市场目光已转向公司新一代抗肿瘤管线。
阿斯利康周一公布，按固定汇率计算，第二季度营收增长5%，达153.8亿美元，市场预期为153.9亿美元；调整后每股收益增长18%至2.63美元，好于市场预期的2.48美元。乳腺癌药物Enhertu销售额大幅增长。
这家英国制药公司以癌症药物领域的强大实力而闻名，陆续推出了包括Tagrisso和Imfinzi在内的多款重磅药物。不过如今投资者更关心公司能否延续这一成功，今年下半年公司将披露多项关键临床试验数据。
阿斯利康仍预计2026年核心每股收益将实现低双位数同比增长，总营收增速为中高个位数。2025年，其营收和利润分别同比增长约8%和11%。
今年以来阿斯利康股价累计下跌8%，导火索是心血管药物Wainua临床数据不及预期。此前公司管理层曾释放该药物前景乐观的信号，最终临床失败令市场大失所望。阿斯利康向来以高标准临床试验体系闻名，晚期新药临床失败的案例十分罕见，此次失利也显著冲击了市场信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.